Global pharma giant Roche has announced that shareholders overwhelmingly approved all proposals put forward by its Board of Directors at the Annual General Meeting. 

 

A total of 594 shareholders, representing 77.22% of Roche’s 106.7 million shares, voted in favor of the Annual and Consolidated Financial Statements, the Remuneration Report, and the Sustainability Report for 2025.

 

Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes. 

 

Addressing shareholders, he said: "The past year was a very successful one for Roche. With our long-term focus, we at Roche are on track — scientifically, financially, and strategically. By combining our expertise in Diagnostics and Pharmaceuticals under one roof, we will continue to have a competitive advantage in the future — one that benefits millions of patients around the world.”

 

The AGM also approved a dividend hike to 9.80 Swiss francs per share and non-voting equity security — marking the 39th consecutive increase. Shareholders authorised the discharge of the Board and Corporate Executive Committee and approved total bonuses for the Executive Committee for 2025 by 95.18% of votes. Future maximum remuneration for the Board and Executive Committee was also approved until the 2027 AGM.

 

All current Board members were re-elected for one-year terms.

 

The AGM appointed KPMG AG as statutory auditors for 2026 and Testaris AG as independent proxy until the 2027 AGM. 

 

Shareholders approved a partial amendment of Roche’s articles of incorporation, including a reduction in nominal share value from CHF 1.00 to CHF 0.001, and the exchange of Genussscheine for Participation Certificates.